Conclusion

The discovery of lepodisiran marks a pivotal advance in the fight against genetic heart disease, bringing new hope to millions affected by elevated Lp(a). Although further research is essential to confirm its full impact on heart health, this innovative drug could finally offer a solution for a once “untreatable” inherited risk. As phase 3 trials continue, universal Lp(a) testing and heightened awareness will be vital for reducing cardiovascular events globally.